Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with ...

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch ...

DZ Bank upgraded Sanofi (SNY) to Buy from Hold with a EUR 122 price target Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Sanofi SA (SNY) stock saw a decline, ending the day at $52.15 which represents a decrease of $-0.82 or -1.55% from the prior close of $52.97. The stock opened at $52.84 and touched a low of $52.14 ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...